Your browser doesn't support javascript.
loading
Antiarrhythmic drugs for atrial fibrillation in the outpatient setting.
Tseng, Andrew S; Desimone, Christopher V; Kowlgi, Gurukripa N.
Afiliação
  • Tseng AS; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
  • Desimone CV; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
  • Kowlgi GN; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA - kowlgi.narayangurukripa@mayo.edu.
Minerva Med ; 114(6): 839-849, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37338231
With burgeoning evidence for early rhythm control in patients with atrial fibrillation (AF), the management of AF in the outpatient setting has become more challenging. The primary care clinician often serves as the frontline in the pharmacologic management of AF. Because of drug interactions and the risk of proarrhythmia, many clinicians remain hesitant about the initiation and chronic management of antiarrhythmic drug prescriptions. However, with the likely increased use of antiarrhythmics for early rhythm control, understanding and familiarity with these medications have likewise become more important, especially since patients with AF probably have other non-cardiac medical conditions that can impact their antiarrhythmic therapy. In this comprehensive review, we provide informative, high-yield cases and edifying references that will help primary care providers become comfortable handling various clinical scenarios.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article